Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-A1811 + SHR-1316 vs Toripalimab + Nab-paclitaxel in PD-L1+ metastatic TNBC
NCT07111832Phase 3Recruiting
- Sponsor
- Suzhou Suncadia Biopharmaceutical
- Start
- Aug 2025
- Primary completion
- Mar 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of trastuzumab rezetecan in triple-negative breast cancer (TNBC), sponsored by Suzhou Suncadia Biopharmaceutical. Started Aug 2025; status: recruiting.
02
Drugs
trastuzumab rezetecan
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT07111832.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07111832.